Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System

In December 2020, the U.S. Food and Drug Administration licensed COVID-19 vaccines for emergency use authorization. We investigated the ocular adverse event reports in patients reported to the Vaccine Adverse Event Reporting System (VAERS) following vaccination against COVID-19. We searched the VAER...

Full description

Bibliographic Details
Main Authors: Cyril N. A. Nyankerh, Akosua K. Boateng, Mary Appah
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/10/6/941
_version_ 1797481568917258240
author Cyril N. A. Nyankerh
Akosua K. Boateng
Mary Appah
author_facet Cyril N. A. Nyankerh
Akosua K. Boateng
Mary Appah
author_sort Cyril N. A. Nyankerh
collection DOAJ
description In December 2020, the U.S. Food and Drug Administration licensed COVID-19 vaccines for emergency use authorization. We investigated the ocular adverse event reports in patients reported to the Vaccine Adverse Event Reporting System (VAERS) following vaccination against COVID-19. We searched the VAERS database for U.S. reports among persons who received COVID-19 vaccines between December 2020 and December 2021. Our goal was to analyze and quantify the ocular adverse events submitted to VAERS to provide clinicians and researchers with a broader view of these ocular side effects. During the analysis period, VAERS received 55,313 adverse event reports and, after data cleaning, 6688 reports met the inclusion criteria. Note that 2229 (33.33%) adverse events were classified as cases of eyelid swelling, ocular hyperemia and conjunctivitis, 1785 (26.69%) as blurred vision and 1322 (19.77%) as visual impairment. Females accounted for 73.8% of adverse event reports and the age group between 40 and 59 years had the most frequent adverse events. A higher proportion of these adverse events reported to VAERS was linked with the Janssen and Moderna COVID-19 vaccines. At the time of vaccination, a high proportion of patients reported conditions like allergies, hypertension, diabetes, thyroid disease, vascular and other autoimmune diseases. A review of these data suggests a possible association between COVID-19 vaccines and ocular adverse events. Physicians are cautioned not only to be aware of this potential problem, but to check any underlying patient conditions, and to carefully document in VAERS within a few weeks of vaccination. Future COVID-19 vaccine safety studies in healthy subjects would help clarify the vaccine’s safety profile.
first_indexed 2024-03-09T22:16:29Z
format Article
id doaj.art-a482e0c788b94d8b8ae1479f3068b1c5
institution Directory Open Access Journal
issn 2076-393X
language English
last_indexed 2024-03-09T22:16:29Z
publishDate 2022-06-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj.art-a482e0c788b94d8b8ae1479f3068b1c52023-11-23T19:21:48ZengMDPI AGVaccines2076-393X2022-06-0110694110.3390/vaccines10060941Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting SystemCyril N. A. Nyankerh0Akosua K. Boateng1Mary Appah2Department of Optometry and Vision Science, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Optometry and Vision Science, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294, USAIn December 2020, the U.S. Food and Drug Administration licensed COVID-19 vaccines for emergency use authorization. We investigated the ocular adverse event reports in patients reported to the Vaccine Adverse Event Reporting System (VAERS) following vaccination against COVID-19. We searched the VAERS database for U.S. reports among persons who received COVID-19 vaccines between December 2020 and December 2021. Our goal was to analyze and quantify the ocular adverse events submitted to VAERS to provide clinicians and researchers with a broader view of these ocular side effects. During the analysis period, VAERS received 55,313 adverse event reports and, after data cleaning, 6688 reports met the inclusion criteria. Note that 2229 (33.33%) adverse events were classified as cases of eyelid swelling, ocular hyperemia and conjunctivitis, 1785 (26.69%) as blurred vision and 1322 (19.77%) as visual impairment. Females accounted for 73.8% of adverse event reports and the age group between 40 and 59 years had the most frequent adverse events. A higher proportion of these adverse events reported to VAERS was linked with the Janssen and Moderna COVID-19 vaccines. At the time of vaccination, a high proportion of patients reported conditions like allergies, hypertension, diabetes, thyroid disease, vascular and other autoimmune diseases. A review of these data suggests a possible association between COVID-19 vaccines and ocular adverse events. Physicians are cautioned not only to be aware of this potential problem, but to check any underlying patient conditions, and to carefully document in VAERS within a few weeks of vaccination. Future COVID-19 vaccine safety studies in healthy subjects would help clarify the vaccine’s safety profile.https://www.mdpi.com/2076-393X/10/6/941COVID-19vaccinationocular complicationsadverse eventsVAERS
spellingShingle Cyril N. A. Nyankerh
Akosua K. Boateng
Mary Appah
Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
Vaccines
COVID-19
vaccination
ocular complications
adverse events
VAERS
title Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
title_full Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
title_fullStr Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
title_full_unstemmed Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
title_short Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
title_sort ocular complications after covid 19 vaccination vaccine adverse event reporting system
topic COVID-19
vaccination
ocular complications
adverse events
VAERS
url https://www.mdpi.com/2076-393X/10/6/941
work_keys_str_mv AT cyrilnanyankerh ocularcomplicationsaftercovid19vaccinationvaccineadverseeventreportingsystem
AT akosuakboateng ocularcomplicationsaftercovid19vaccinationvaccineadverseeventreportingsystem
AT maryappah ocularcomplicationsaftercovid19vaccinationvaccineadverseeventreportingsystem